<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694954</url>
  </required_header>
  <id_info>
    <org_study_id>E20270</org_study_id>
    <secondary_id>Internal tracking #1763</secondary_id>
    <nct_id>NCT00694954</nct_id>
  </id_info>
  <brief_title>Capsule Endoscopy vs Standard of Care for Obscure Intestinal Bleeding</brief_title>
  <official_title>A Randomized Controlled Trial of Capsule Endoscopy vs Standard Care in Patients With Iron Deficiency Anemia With Suspected Obscure / Occult Gastrointestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Heritage Foundation for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Calgary Health Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of capsule endoscopy (CE) in patients with obscure / occult gastrointestinal (GI)
      bleeding remains unclear. This pragmatic randomized controlled trial is designed to determine
      the diagnostic yield and clinical outcomes of patients with obscure GI bleeding who receive
      CE compared to those who receive usual standard care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with iron deficiency anemia from suspected occult GI bleeding will be randomized to
      receive CE or usual standard care following a negative gastroscopy and colonoscopy. Our
      primary outcome measure (diagnostic yield) and secondary outcome measures (noted below) will
      be determined after one year of followup. Patients with have a minimum of one year of
      clinical followup. Direct health care costs in each arm of the study will be determined after
      a minimum of two years of followup.

      An economic evaluation based on the results of the clinical trial is also planned.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic yield</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of blood transfusions</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospitalizations for GI bleeding/anemia</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of GI-related procedures and investigations</measure>
    <time_frame>48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure-related complications</measure>
    <time_frame>48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>48</time_frame>
    <description>measured by 1) SF36 - 8 domains + PCS/MCS, 2) GI Quality of Life Index (GIQLI), 3) EQ-5D - index + visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health care costs</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wireless capsule endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diagnostic Test - Given Imaging Pillcam</intervention_name>
    <description>Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.
Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Capsule endoscopy</other_name>
    <other_name>Given Imaging Pillcam</other_name>
    <other_name>Pill camera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostics</intervention_name>
    <description>Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients age over 18years with iron deficiency anemia (IDA). IDA is defined as
             hemoglobin &lt;137g/L in men or &lt;120g/L in women with serum ferritin level &lt;22ug/L in men
             and &lt;10ug/L in women.

          2. Eligible patients should have a negative gastroscopy and negative colonoscopy within 1
             year prior to entry into study.

          3. Negative celiac screen and /or negative small bowel biopsies

        Exclusion Criteria:

          1. Overt gastrointestinal bleeding

          2. Premenopausal women with menorrhagia

          3. Known or suspected small bowel obstruction

          4. Serious medical co-morbidities precluding surgery given the risk of capsule impaction

          5. Pregnancy

          6. Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine J. Dube, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Robert Hilsden</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Iron deficiency anemia</keyword>
  <keyword>Wireless capsule endoscopy</keyword>
  <keyword>Obscure-occult gastrointestinal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

